EGFR anticorps

N° du produit ABIN265396

Cet anticorps Lapin Polyclonal détecte spécifiquement EGFR dans WB, IHC (p) et EIA. Il présente une réactivité envers Humain, Souris et Rat.

Aperçu rapide pour EGFR anticorps (ABIN265396)

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EGFR est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Détail du produit anti-EGFR anticorps

Specificité: This antibody detects endogenous levels of Actin-pan protein (region surrounding His672).

Réactivité croisée (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen

Pureté: > 95 % pure by SDS-PAGE

Information d'application

Indications d'application: ELISA: 1: 10000approx. 1: 40000. WB: 1: 500approx. 1: 1000. IHC: 1: 50approx. 1: 200.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2., 0.05 % Sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur EGFR

Antigène: EGFR (Epidermal Growth Factor Receptor (EGFR))

Autre désignation: EGFR / ERBB1

Sujet: The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Exons in the EGFR gene product are frequently either deleted or duplicated to produce deletion mutants (DM) or tandem duplication mutants (TDM), respectively, which are detected at various molecular weights. EGFR binds several ligands including epidermal growth factor (EGF), transforming growth factor α (TGFα), Amphiregulin and heparin binding-EGF (HB-EGF). Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

Poids moléculaire: approx. 134, 175 kDa

ID gène: 1956

NCBI Accession: NP_005219

UniProt: P00533

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins